Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193
- PMID: 29961843
- PMCID: PMC6321845
- DOI: 10.1093/cid/ciy525
Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193
Abstract
We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.
References
-
- Jørgensen S, Sunde M, Berg E, et al. Fluoroquinolone resistant Escherichia coli ST1193 – another global successful clone? 27th ECCMID 2017; P0204.
-
- Kim Y, Oh T, Nam YS, Cho SY, Lee HJ. Prevalence of ST131 and ST1193 among bloodstream isolates of Escherichia coli not susceptible to ciprofloxacin in a tertiary care university hospital in Korea, 2013–2014. Clin Lab 2017; 63:1541–3. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases